Monte Rosa Therapeutics GLUE Estimates

NASDAQ GLUE
$14.13 -0.25 (-1.74%)
As of: Sep 4, 2026 · 11:47 AM EDT
Analyst Estimates

Monte Rosa Therapeutics, Inc. Revenue Estimates

Periods 27
Next Period Q2 26
Consensus 12.47 M

Analysts expect Monte Rosa Therapeutics, Inc. to report revenue of 12.47 M for Q2 26, against a range of 11.97 M to 12.97 M. The most recent reported quarter, Q1 26, came in at 4.20 M, a 63.2% miss against the 11.40 M consensus.

Metric Q2 24Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29Q1 30Q2 30Q3 30Q4 30
Reported (Actual) 4.70 M9.20 M60.60 M84.93 M23.19 M12.80 M2.80 M4.20 M--------
High Estimate 1.39 M2.88 M46.45 M42.47 M7.37 M8.38 M18.13 M12.08 M12.97 M15.37 M15.06 M5.74 M1.36 M11.44 M15.79 M12.58 M
Low Estimate 1.17 M2.57 M43.64 M35.71 M6.88 M7.19 M14.88 M10.73 M11.97 M13.82 M12.85 M4.76 M1.22 M10.64 M14.16 M11.09 M
Consensus Estimate 1.28 M2.73 M45.04 M39.09 M7.13 M7.79 M16.50 M11.40 M12.47 M14.59 M13.96 M5.25 M1.29 M11.04 M14.98 M11.84 M
Analyst Estimates

Monte Rosa Therapeutics, Inc. Earnings Per Share (EPS) Estimates

Periods 27
Next Period Q2 26
Consensus -0.36

Analysts expect Monte Rosa Therapeutics, Inc. to report earnings per share of -0.36 for Q2 26, against a range of -0.38 to -0.34. The most recent reported quarter, Q1 26, came in at -0.45, a 18.4% miss against the -0.38 consensus.

Metric Q2 24Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29Q1 30Q2 30Q3 30Q4 30
Reported (Actual) -0.43-0.290.160.57-0.15-0.33-0.54-0.45--------
High Estimate -0.52-0.470.020.00-0.33-0.34-0.34-0.35-0.34-0.38-0.42-0.55-0.53-0.49-0.50-0.46
Low Estimate -0.58-0.530.020.00-0.37-0.38-0.40-0.41-0.38-0.44-0.46-0.63-0.63-0.59-0.58-0.52
Consensus Estimate -0.55-0.500.020.00-0.35-0.36-0.37-0.38-0.36-0.41-0.44-0.59-0.58-0.54-0.54-0.49